SI-BONE Inc. (NASDAQ:SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) compete with each other in the Medical Appliances & Equipment sector. We will analyze and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for SI-BONE Inc. and Cesca Therapeutics Inc.

Profitability

Table 2 shows SI-BONE Inc. and Cesca Therapeutics Inc.s return on equity, net margins and return on assets.

Liquidity

SI-BONE Inc. has a Current Ratio of 13.1 and a Quick Ratio of 12.7. Competitively, Cesca Therapeutics Inc.s Current Ratio is 1.6 and has 0.8 Quick Ratio. SI-BONE Inc.s better ability to pay short and long-term obligations than Cesca Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for SI-BONE Inc. and Cesca Therapeutics Inc.

Meanwhile, Cesca Therapeutics Inc.s consensus target price is $7.5, while its potential upside is 45.07%.

Insider & Institutional Ownership

The shares of both SI-BONE Inc. and Cesca Therapeutics Inc. are owned by institutional investors at 74.7% and 1.8% respectively. About 3% of SI-BONE Inc.s share are held by insiders. Insiders Comparatively, held 30.91% of Cesca Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year SI-BONE Inc. had bearish trend while Cesca Therapeutics Inc. had bullish trend.

Summary

SI-BONE Inc. beats on 7 of the 9 factors Cesca Therapeutics Inc.

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood. The company also offers MarrowXpress system, a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; BioArchive system, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use; and manual disposables bag sets for use in the processing and cryogenic storage of cord blood. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to see the original:
SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly